Proactive Investors - Run By Investors For Investors

Orgenesis subsidiary Masthercell Global unveils new production wing at Belgian plant

The new wing includes two development laboratories, a quality control laboratory and clean rooms
scientist in a lab
Maggie De Block, Belgium's Public Health and Social Affairs minister, attended the launch of Masthercell's new production wing

Masthercell Global, a subsidiary of Orgenesis Inc (NASDAQ:ORGS), the developer and manufacturer of advanced cell therapies, has unveiled a new production wing at its Belgium site.

The expansion of its current Belgium plant gives Masthercell, which is a cell therapy-focused contract development and manufacturing organization, five additional state-of-the-art clean rooms. The new wing also includes two development laboratories, a quality control laboratory and additional warehouse capabilities.

READ: Orgenesis CEO says companies looking for ways to get costs of medicine down

Maggie De Block, Belgium’s Public Health and Social Affairs minister, and Willy Borsus, the minister-president of Wallonia were in attendance for the launch of the new facility.

“The cell therapy industry, and specifically our partners, are eager to have access to reliable and additional state-of-the-art facilities for their commercial projects,” said Dr Denis Bedoret, managing director of Masthercell in a statement.

“Our objective is to help them access the market faster with tailor-made capabilities. Today, we are pleased to offer these key assets to our partners and more widely to any cell therapy company facing a lack of production or development capacities,” Bedoret added.

Masthercell is also backed by Great Point Partners LLC, a healthcare investment firm based in Greenwich, Connecticut.

Orgenesis is a biopharmaceutical company focused on cell-therapy development and support services.

Via its Masthercell Global subsidiary, Orgenesis works with cell therapy organizations to provide business modeling as well as help with manufacturing and technology selection in a bid to speed up the arrival of their therapies to the market.

Each clean room of the new production wing is 30 square meters and boasts independent HVAC systems while the new production wing is 600 square meters.

Orgenesis shares jumped 9.1% to finish Thursday at $6.23.

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use